Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes
暂无分享,去创建一个
Georges Michel | Erik Muls | C. Brotons | E. Muls | F. Nobels | M. Hermans | Frank Nobels | Michel P. Hermans | Carlos Brotons | M. Elisaf | G. Michel | H. Vandenberghe | Moses Elisaf | Hans Vandenberghe
[1] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[2] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[3] Eric R. Ziegel,et al. Biostatistical Methods , 2002, Technometrics.
[4] S. Iliffe,et al. Bmc Medical Research Methodology Open Access the Hawthorne Effect: a Randomised, Controlled Trial , 2007 .
[5] Li Yan,et al. Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. , 2011, Chinese medical journal.
[6] J. Wens,et al. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP. , 2011, Primary care diabetes.
[7] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[8] Sylvia J. Hysong,et al. Meta-Analysis: Audit and Feedback Features Impact Effectiveness on Care Quality , 2009, Medical care.
[9] J J Allison,et al. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. , 2001, JAMA.
[10] A pragmatic cluster randomised controlled trial of a Diabetes REcall And Management system: the DREAM trial , 2007, Implementation science : IS.
[11] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[12] S. Ebrahim. Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. , 1998, Health technology assessment.
[13] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[14] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[15] B. Neal. The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .
[16] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[17] Rury R. Holman,et al. Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .
[18] Neil Chapman,et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.
[19] C. Brotons,et al. Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus , 2011, Cardiovascular diabetology.
[20] M. Burnier,et al. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. , 2006, American journal of hypertension.
[21] S. Kische,et al. O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .
[22] W. J. Elliott,et al. Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review , 2008 .
[23] F. J. Roethlisberger,et al. Management and the Worker , 2003 .
[24] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[25] A. Turchin,et al. Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. , 2011, Archives of internal medicine.
[26] Paul E. Johnson,et al. Customized Feedback to Patients and Providers Failed to Improve Safety or Quality of Diabetes Care , 2009, Diabetes Care.
[27] S. Haffner,et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.
[28] William Branch,et al. Clinical Inertia , 2001, Annals of Internal Medicine.
[29] David Machin,et al. Sample Size Tables for Clinical Studies , 1997 .
[30] S. Jacob,et al. Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap? , 2010, Advances in therapy.
[31] C. Brotons,et al. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries , 2013, European journal of preventive cardiology.
[32] G. W. Snedecor. Statistical Methods , 1964 .
[33] R. Stolk,et al. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. , 2009, Family practice.
[34] Residual vascular risk in T2DM: the next frontier , 2011 .
[35] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.
[36] W. Gillanders,et al. Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial. , 2011, Archives of internal medicine.
[37] F. J. Roethlisberger,et al. Management and the Worker , 1941 .
[38] B. Davis,et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.
[39] M. Vandervoort,et al. Barriers to Blood Pressure Control: A STITCH Substudy , 2011, The Journal of Clinical Hypertension.
[40] Jane M. Young,et al. Does telling people what they have been doing change what they do? A systematic review of the effects of audit and feedback , 2006, Quality and Safety in Health Care.
[41] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[42] M. Godwin,et al. Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's, Nfld. , 2010, Canadian family physician Medecin de famille canadien.